Commentary | Published:

Professor's little helper

Nature volume 450, pages 11571159 (20 December 2007) | Download Citation

Subjects

The use of cognitive-enhancing drugs by both ill and healthy individuals raises ethical questions that should not be ignored, argue Barbara Sahakian and Sharon Morein-Zamir.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    , , , & MRC-CFAS. PSSRU Discussion Paper 1728 (2003).

  2. 2.

    et al. J. Clin. Psychiatry 66, 1122–1129 (2005).

  3. 3.

    & Schizophr. Res. 17, 123–129 (1995).

  4. 4.

    , & Schizophr. Bull. doi:10.1093/schbul/sbm090 (2007).

  5. 5.

    et al. Neuropsychopharmacol. 29, 1363–1373 (2004).

  6. 6.

    Attention-Deficit Hyperactivity Disorder: A Handbook for Diagnosis and Treatment 3rd edn (Guilford, New York, 2006).

  7. 7.

    et al. J. Am. Acad. Child Adolesc. Psychiatry 46, 1015–1027 (2007).

  8. 8.

    et al. Nature Rev. Neurosci. 5, 421–425 (2004).

  9. 9.

    & Brain Cogn. 53, 82–94 (2003).

  10. 10.

    et al. Psychopharmacol. 131, 196–206 (1997).

Download references

Author information

Affiliations

  1. Barbara Sahakian and Sharon Morein-Zamir are at the University of Cambridge, Department of Psychiatry and the MRC/Wellcome Trust Behavioural and Clinical Neuroscience Institute, Cambridge CB2 2QQ, UK.

    • Barbara Sahakian
    •  & Sharon Morein-Zamir

Authors

  1. Search for Barbara Sahakian in:

  2. Search for Sharon Morein-Zamir in:

Competing interests

Barbara Sahakian consults for several pharmaceutical companies and for Cambridge Cognition. She also has shares in CeNeS.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/4501157a

Join the discussion at: http://network.nature.com/forums/naturenewsandopinion/816

Further reading Further reading

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing